<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tugce Schmitt</style></author><author><style face="normal" font="default" size="100%">H Antoine-Poirel</style></author><author><style face="normal" font="default" size="100%">Emilie Cauët</style></author><author><style face="normal" font="default" size="100%">Marie Delnord</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Unlocking the genomic landscape: Results of the Beyond 1 Million Genomes (B1MG) pilot in Belgium towards Genomic Data Infrastructure (GDI)</style></title><secondary-title><style face="normal" font="default" size="100%">Health Policy</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Beyond 1 Million Genomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomic Data Infrastructure</style></keyword><keyword><style  face="normal" font="default" size="100%">implementation</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-05-2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">143</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;h4&gt;&lt;strong style=&quot;color:#69aa41;&quot;&gt;Abstract&lt;/strong&gt;&lt;/h4&gt;

&lt;p&gt;Genomic medicine has great potential to offer insights into how humans’ genetic variation can affect their health, prevention options and treatment responses. The Beyond 1 Million Genomes (B1MG) project was kicked off in 2020 with the aim of building a federated network of genomic data in Europe, in which Belgium took part as a piloting country. B1MG developed a framework to enable all interested countries to self-evaluate the level of maturity of national genomic medicine practices following a common matrix, called Maturity Level Model (MLM), that contained 49 indicators across eight domains: I. Governance and strategy; II. Investment and economic model; III. Ethics, legislation and policy; IV. Public awareness and acceptance; V. Workforce skills and organisation; VI. Clinical organisation, infrastructure and tools; VII. Clinical genomics guidelines and infrastructure; and VIII. Data management, standards and infrastructure. The ongoing Genomic Data Infrastructure (GDI) project aims to capitalise on the experience of B1MG piloting countries and their MLM results. In this paper, we present the qualitative and quantitative outcomes of B1MG MLM assessment in Belgium and discuss their relevance to GDI. The insights gained from this study can be helpful for steering future policy directions and interventions on genomics in Belgium and beyond.&lt;/p&gt;
</style></abstract></record></records></xml>